AMYVID

This brand name is authorized in Austria, Estonia, Croatia, Ireland, Japan, Lithuania, Poland, United States

Active ingredients

The drug AMYVID contains one active pharmaceutical ingredient (API):

1 Florbetapir ¹⁸F UNII 6W15Z5R0RU - FLORBETAPIR F-18

Florbetapir ¹⁸F binds to β-amyloid plaques and the ¹⁸F isotope produces a positron signal that is detected by a PET scanner. Florbetapir ¹⁸F is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. Read about Florbetapir ¹⁸F

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
AMYVID Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
V09AX05		V Various → V09 Diagnostic radiopharmaceuticals → V09A Central nervous system → V09AX Other central nervous system diagnostic radiopharmaceuticals
Discover more medicines within V09AX05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1618657, 1618668, 1618679, 1618680
Country: JP	医薬品医療機器総合機構	Identifier(s): 43004A2A1029
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1069110, 1069111, 1069112, 1069113
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100305831, 100305848
Country: US	FDA, National Drug Code	Identifier(s): 0002-1200